EGFR and non-small cell lung carcinoma: Acquired resistance to first/second-generation EGFR-TKIs is most commonly mediated by a secondary mutation in the EGFR gene, resulting in a T790M substitution that occurs in approximately 60% of NSCLC patients upon progression on first-line treatment [9].